Factor VII recombinante activado en pacientes no hemofílicos con hemorragia aguda grave en la Unidad de Terapia Intensiva

background. severe hemorrhage is a frequent complication with multiple etiologies and high morbi-mortality observed among critically ill patients. recombinant factor viia (rfviia) constitutes a new therapeutic alternative. objective. analyze the evolution in a non-hemophiliac patient group with severe hemorrhage treated with rfviia. material and methods. ten non-hemophiliac patients with severe hemorrhage, five men and five women between 18 and 74 years, were included and treated with rfviia. we used a t test for statistic analyses. significance was set at p < 0.001. results. among patients treated with rfviia, hemorrhage was controlled and the use of blood products was significantly diminished (p < 0.001). coagulation tests, fibrinogen levels, platelet count and perfusion parameters increased significantly (p < 0.001). conclusions. rfviia is a therapeutic alternative for the treatment of severe hemorrhage not controlled by conventional management.